

**LACHMAN CONSULTANT SERVICES, INC.**  
CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES

1600 STEWART AVENUE, WESTBURY, NY 11590  
(516) 222-6222 • FAX (516) 683-1887

November 11, 2002

**OVERNIGHT COURIER 11/11/02**

Dockets Management Branch  
Food and Drug Administration (HFA-305)  
Department of Health and Human Services  
5630 Fishers Lane, Room 1061  
Rockville, MD 20852

Re: Withdrawal of Citizen Petition Docket No. 01P-0377

Dear Sir or Madam:

On August 29, 2001, Lachman Consultant Services, Inc (LCS) on behalf of a client submitted the above-referenced petition requesting the Commissioner of the Food and Drug Administration for a finding that Methadone Hydrochloride Tablets, 15 mg, 20 mg, 30 mg, and 40 mg were suitable for submission in an abbreviated new drug application. That petition referenced Dolophine® Tablets (Methadone Hydrochloride), 5 mg and 10 mg approved under NDA 06-134 as the basis for the proposed change.

At this time LCS would like to withdraw the above-referenced petition from Agency consideration without prejudice to refiling.

Sincerely,

*Robert Pollock* (BH)

Robert W. Pollock  
Vice President

RP/bh/m

cc: G. Davis  
M. Shimer

**01P-0377**

**WDL 1**

M03p2315a